Skip to main content
Premium Trial:

Request an Annual Quote

Genomics England Taps Iqvia for Clinical-Genomic Data Integration

NEW YORK (GenomeWeb) – Genomics England is teaming with analytics firm Iqvia to develop a platform for bringing together clinical and genomic data in support of evidence-based precision medicine and drug discovery.

Under a deal announced today, Durham, North Carolina-based Iqvia — formerly known as Quintiles IMS — will offer its E360 analytics technology to authorized users of Genomics England's database of de-identified genomic and phenotypic records. The British genomics program said that the partnership will strengthen the UK's position as a global life sciences hub.

After the integrated genomic-clinical build of E360 goes online in 2019, Iqvia and Genomics England expect to serve academic and commercial researchers alike in genotype-phenotype association studies, comparative efficacy and safety trials, and burden-of-illness analytics.

"Our collaboration advances the analysis of these complex datasets, which could accelerate the discovery of precision therapies [and] improve access and health outcomes," Jon Resnick, president of Iqvia Real-World and Analytics Solutions, said in a statement.

"Working together, we can unlock the potential of these datasets to advance research and benefit patients in the UK as well as those throughout the world," added Genomics England Chief Commercial Officer Joanne Hackett.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.